Drug development injectablesAcusphere, USA
Acusphere was listed on NASDAQ in 2003.
Antibody technology platformAdnexus Therapeutics, USA
Adnexus was acquired by Bristol-Myers Squibb for $430 million in 2007.
Drug development oncologyAdvanced Accelerator Applications, France
AAA was listed on NASDAQ in 2015, then acquired by Novartis for $3.9 billion in 2017.
Antibody technology platformAgensys, USA
Agensys was acquired by Astellas for up to $537 million in 2007.
Kidney and metabolic disordersAllena Pharmaceuticals
Allenawas listed on NASDAQ in 2017.
Women's healthAlydia Health, USA
Alydia was acquired by Organon for up to $240 million in 2021.
Drug development antiviralsAnadys Pharmaceuticals, USA
Anadys Pharmaceuticals was listed on NASDAQ in 2004.
Drug development inflammationAnaptysBio, USA
AnaptysBio, Inc. was listed on NASDAQ in 2017.
Drug development cardiovascularAnthera, USA
Anthera was listed on NASDAQ in 2010.
Drug development and formulationAPR Applied Pharma Research
APR Applied Pharma Research was acquired by Relief Therapeutics for CHF66.5M on Jun 29, 2021.
CNS diseasesAptinyx
Aptinyx was listed on NASDAQ in 2018.
Drug development oncologyARMO Biosciences, USA
ARMO Biosciences was acquired by Eli Lilly for 1.6 billion in May 2018 .
Drug development antibacterialsArpida, Switzerland
Arpida was listed on SIX Swiss Exchange in 2005.
Specialty pharmaAspreva, Canada
Apreva was listed on NASDAQ in 2005 and acquired by Galenica in 2007 for $915 million.
Medical device pulmonary diseasesAsthmatx, USA
Asthmatx was sold to Boston Scientific for up to $443 million in 2010.
Drug development cardiovascularAxovan, Switzerland
Axovan was acquired by Actelion in 2004 for up to CHF252 million.
Protein technology platformBarofold, USA
BaroFold applies its Pressure Enabled Protein Manufacturing (PreEMT™) technology to improve the tolerability, efficacy and safety of a wide variety of protein therapeutics for biopharma companies and research institutions.
Drug development antibacterials and antifungalsBasilea Pharmaceutica, Switzerland
Basilea was listed on SIX Swiss Exchange in 2004.
Medical device neurologyBioControlMedical, Switzerland/Israel
BioControl Medical develops implantable medical devices to treat disorders of the autonomic nervous system.
CNS diseasesBioshin
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant
BiopharmaceuticalBiovitrum, Sweden
Biovitrum was listed on OMX Stockholm in 2006. In 2010 Biovitrum and Swedish Orphan merged forming Swedish Orphan Biovitrum.
Specialty diagnosticsBrahms, Germany
Brahms was acquired by ThermoFischer for $470 million in 2009.
Targeted protein degradationC 4 Therapeutics, USA
C4 Therapeutics was listed on NASDAQ in 2020.
Drug discovery inflammationCardion, Germany
Cardion was acquired by Roche in 2003.
Drug development inflammationChemoCentryx, USA
ChemoCentryx was listed on NASDAQ in 2012.
Specialty pharmaChina Nuokang, China
China Nuokang was listed on NASDAQ in 2009.
Drug development cardiovascularCorgentech, USA
Corgentech was listed on NASDAQ in 2004.
Drug development cardiovascularCorvidia Therapeutics, USA
Corvidia was acquired by Novo Nordisk for up to $2.1 billion in 2020.
DiagnosticsCuretis, Germany
Curetis was listed on Euronext in 2015 and then merged with NASDQ listed OpGen in 2019.
Drug development cardiovascularCytokinetics, USA
Cytokinetics was listed on NASDAQ in 2004.
Vaccine technology platformCytos Biotechnology, Switzerland
Cytos was listed on SIX Swiss Exchange in 2002.
Antibody technology platformDelenex Therapeutics, Switzerland
Delenex was acquired by Cell Medica in 2016.
Drug development orphan diseasesEiger BioPharmaceuticals, USA
Eiger BioPharmaceuticals was listed on NASDAQ in 2016.
Medical device orthopedic implantsEllipse Technologies, USA
Ellipse Technologies was acquired by NuVasive (Nasdaq: NUVA) in 2016.
Infectious diseasesEnanta Pharmaceuticals, USA
Enanta was listed on NASDAQ in 2013.
Drug development ophthalmologyEsbatech, Switzerland
Esbatech was acquired by Alcon (Novartis) for up to $589 million.
Drug development oncologyForbius, USA
Forbius was acquired by Bristol-Myers Squibb in 2020.
Drug development oncologyGalera Therapeutics, USA
Galera was listed on NASDAQ in 2019.
Drug development oncologyGemin X, Canada
Gemin X was acquired by Cephalon for $225 million in 2003.
Drug development genetic diseasesHomology Medicines, USA
Homology was listed on NASDAQ in 2018.
Drug development oncology and autoimmune diseasesHookipa Biotech
Drug development inflammationIcagen, USA
Icagen was listed on NASDAQ in 2004.
Drug development oncologyInfinity Pharmaceuticals, USA
Infinity Pharmaceuticals was listed on NASDAQ in 2006.
Percutaneous spine implantsInterventional Spine, USA
Interventional Spine was acquired DePuy Synthes in 2017.
OncologyiTeos Therapeutics
Drug development oncologyKolltan Pharmaceuticals, USA
Kolltan Pharmaceuticals was acquired by Celldex for up to $235 million.
Medical device transplantologyLifeline Scientific, USA
Lifeline Scientific was listed on AIM London in 2008.
Drug distributionMediservice, Switzerland
Mediservice was acquired by Galenica in 2007.
Drug development oncologyMicromet, Germany/USA
Micromet was listed on NASDAQ in 2003 and subsequently acquired by Amgen for $1.16 billion.
Medical device neurologyMicrus Endovascular, USA
Micrus was listed on NASDAQ in 2005 and acquired by J&J /DePuy in 2010.